Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

BACKGROUND: Nintedanib (Ofev(®)) and pirfenidone (Esbriet(®)) are recommended by international guidelines as treatment options for idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To compare the cost-effectiveness of nintedanib with that of pirfenidone for the treatment of IPF from a Belgian healthc...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinciog, C., Diamantopoulos, A., Gentilini, A., Bondue, B., Dahlqvist, C., Froidure, A., Wuyts, W. A., Soulard, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426351/
https://www.ncbi.nlm.nih.gov/pubmed/31939146
http://dx.doi.org/10.1007/s41669-019-00191-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426351/
https://www.ncbi.nlm.nih.gov/pubmed/31939146
http://dx.doi.org/10.1007/s41669-019-00191-w

Ejemplares similares